Innovations in Implantable Electronics

Neurostimulation and Continuous Glucose Monitoring Drive Growth Opportunities for Implantable Electronics

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

The technology and innovation study on implantable electronics captures active implantable medical devices used for support of debilitating function in the human body or to completely replace the function of the diseased organ. The segments covered include: cochlear implants, retinal implants, implantable continuous glucose monitoring (CGM), implantable infusion pumps, cardiovascular implantable electronic devices, and implantable neurostimulation. Recent innovations and key innovators are captured under each segment. The study also covers reimbursement scenario of each of these devices in North America, Europe and Asia-Pacific. Regulatory framework and insurance coverage are considered to be the key factors th

Table of Contents

1. Executive Summary1.1 Scope of Research1.2 Research Process Methodology1.2 Research Methodology Explained1.3 Key Findings2. Cochlear Implants2.1 Adoption of Cochlear Implants Remains Extremely High in Developed Nations2.2 Cochlear Implants Market Remains Consolidated Even after Decades2.3 IP Scenario of Cochlear Implant Manufacturers3. Retinal Implants3.1 Sizeable Addressable Market for Retinal Implants3.2 Flexible Regulations to Boost the Commercialization of Retinal Implants3.3 IP Scenario of Top Patent Assignees in Retinal Implants4. Implantable Neurostimulation4.1 Spinal Cord Stimulation Continues to Attract Maximum Adoption4.2 Leadless Neurostimulators with Prolonged Battery Life Expected in the Future4.3 Medtronic Offers the Largest Range of Implantable Neurostimulators4.4 Hypoglossal Nerve Stimulation among the Most Researched Modulation Techniques in Recent Times4.5 IP Scenario of Companies Developing Implantable Neurostimulators5. Implantable Infusion Pumps5.1 Implantable Infusion Pumps Hold Promise in Delivering Sustained-Release Medications5.2 Better Insurance Coverage Expected for Implantable Infusion Pumps5.3 IP Scenario of Top Patent Assignees in Implantable Infusion Pumps6. Implantable Continuous Glucose Monitoring (CGM)6.1 Prospects for Implantable Sensors in Continuous Glucose Monitoring (CGM)6.2 Eversense Remains the Only Commercially Available Implantable CGM6.3 IP Scenario of Companies Developing Implantable CGMs7. Cardiovascular Implantable Electronic Device (CIED)7.1 Cardiovascular Implantable Devices Segment is the Most Mature in the Implantable Electronics Sector7.2 Cardiac Pacemakers will Continue to Enjoy Maximum Share in the Cardiovascular Segment7.3 Better Compatibility with MRI has Boosted the Growth of CIEDs7.4 IP Scenario of Top Patent Assignees Developing Cardiovascular Implantable Devices8. Impact Assessment and Analysis8.1 Regulatory Bodies and Insurance Coverage Hold Maximum Weightage in the Value Chain8.2 Market Drivers8.3 Drivers Explained8.3 Drivers Explained (continued)8.4 Market Challenges8.5 Challenges Explained8.5 Challenges Explained (continued)9. Reimbursement Scenario9.1 Payers and Providers Hold Significance in Insurance Coverage9.2 North America is the Strongest Region for Implantable Device Insurance Coverage9.3 Europe Presents a Mature Private Health Insurance Model9.4 Increasing Focus on Healthcare Reforms in the Asia-Pacific Region10. Funding & Partnership Assessment10.1 Cardiovascular and Cochlear Implants Research Receives Maximum Funding from the NIH10.2 NIH Funds Some of the Key Groundbreaking Projects in Implantable Electronics10.3 Supportive Government Funding for Development of Retinal Implants10.4 Private Investors Demonstrate Encouraging Sponsorship toward Neurostimulator Manufacturers10.5 Development of Implantable Infusion Pumps Requires Substantial Support from Collaborators and Investors10.6 Cochlear Implant Manufacturers Experience Positive Growth Due to Solid YoY Revenues10.7 Huge Investments from Private Investors Boost the R&D Efforts for Implantable CGMs10.8 Cardiovascular Implants Remain Active Space for M&As11. Opportunity Evaluation11.1 Next-Generation Cochlear Implants to Showcase Rapid Wireless Charging11.2 Neuroprosthetics to be Integrated with Wearable Neurostimulation11.3 Internet-of-Things (IoT) is Expected to be Integrated with a Number of Implantable Devices in the Future11.4 Strategic Recommendations for Global Manufacturers12. Growth Opportunities and Companies to Action12.1 Growth Opportunity 1: Point-of-Care Neurostimulation12.2 Growth Opportunity 2: Smart Bandages for Wound Care12.3 Growth Opportunity 3: Electroceuticals12.4 Growth Opportunity 4: Continuous Glucose Monitoring12.5 Growth Opportunity 5: Smarter Drug Delivery12.6 Strategic Imperatives for Success and Growth of Implantable Electronics13. Key Contacts & Patents13.1 Global Patents13.1 Global Patents (continued)13.1 Global Patents (continued)13.1 Global Patents (continued)13.1 Global Patents (continued)13.2 Key Contacts13.3 Legal Disclaimer14. The Frost & Sullivan StoryThe Journey to Visionary Innovation14.1 The Frost & Sullivan Story14.2 Value Proposition: Future of Your Company & Career14.3 Global Perspective14.4 Industry Convergence14.5 360º Research Perspective14.6 Implementation Excellence14.7 Our Blue Ocean Strategy

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.